Share on StockTwits

Conatus Pharmaceuticals (NASDAQ:CNAT) issued its quarterly earnings data on Wednesday. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.06, AnalystRatings.Net reports.

Conatus Pharmaceuticals (NASDAQ:CNAT) traded up 0.26% on Wednesday, hitting $7.78. The stock had a trading volume of 712,344 shares. Conatus Pharmaceuticals has a 1-year low of $5.06 and a 1-year high of $15.67. The stock has a 50-day moving average of $7.90 and a 200-day moving average of $8.22. The company’s market cap is $120.0 million.

On a related note, analysts at Roth Capital initiated coverage on shares of Conatus Pharmaceuticals in a research note on Friday, June 13th. They set a “buy” rating and a $19.00 price target on the stock. Four equities research analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and a consensus target price of $16.50.

Conatus Pharmaceuticals Inc is a biotechnology company focused on the development and commercialization of medicines to treat liver disease.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.